Literature DB >> 16970562

Time to question long-term safety of routine scheduled inhaled beta-2-agonist treatment for COPD.

Douglas C McCrory.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16970562      PMCID： PMC1831643          DOI： 10.1111/j.1525-1497.2006.00602.x

Source DB:  PubMed          Journal:  J Gen Intern Med        ISSN： 0884-8734            Impact factor:   5.128


× No keyword cloud information.
  5 in total

1.  Meta-analysis: anticholinergics, but not beta-agonists, reduce severe exacerbations and respiratory mortality in COPD.

Authors:  Shelley R Salpeter; Nicholas S Buckley; Edwin E Salpeter
Journal:  J Gen Intern Med       Date:  2006-10       Impact factor: 5.128

Review 2.  Statistical treatment of exacerbations in therapeutic trials of chronic obstructive pulmonary disease.

Authors:  Samy Suissa
Journal:  Am J Respir Crit Care Med       Date:  2006-01-26       Impact factor: 21.405

Review 3.  Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: National Heart, Lung, and Blood Institute and World Health Organization Global Initiative for Chronic Obstructive Lung Disease (GOLD): executive summary.

Authors:  R A Pauwels; A S Buist; P Ma; C R Jenkins; S S Hurd
Journal:  Respir Care       Date:  2001-08       Impact factor: 2.258

4.  Routine nebulized ipratropium and albuterol together are better than either alone in COPD. The COMBIVENT Inhalation Solution Study Group.

Authors: 
Journal:  Chest       Date:  1997-12       Impact factor: 9.410

Review 5.  Ipratropium bromide versus short acting beta-2 agonists for stable chronic obstructive pulmonary disease.

Authors:  S Appleton; T Jones; P Poole; L Pilotto; R Adams; T J Lasserson; B Smith; J Muhammad
Journal:  Cochrane Database Syst Rev       Date:  2006-04-19
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.